Difference between revisions of "Avatrombopag (Doptelet)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
m (→Also known as) |
||
| Line 21: | Line 21: | ||
[[Category:Immune thrombocytopenia (ITP) medications]] | [[Category:Immune thrombocytopenia (ITP) medications]] | ||
| + | [[Category:Thrombocytopenia in liver disease medications]] | ||
[[Category:FDA approved in 2018]] | [[Category:FDA approved in 2018]] | ||
Revision as of 02:24, 5 August 2018
Mechanism of action
Thrombopoietin receptor agonist
Diseases for which it is used
- Bussel JB, Kuter DJ, Aledort LM, Kessler CM, Cuker A, Pendergrass KB, Tang S, McIntosh J. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014 Jun 19;123(25):3887-94. Epub 2014 May 6. link to original article PubMed
History of changes in FDA indication
- 5/21/2018: FDA approved "for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure."
Also known as
- Code names: E5501, YM477, AKR 501
- Brand name: Doptelet